Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (Weighted Average): 2014-2025

Historic Shares Outstanding (Weighted Average) for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to $945.3 million.

  • ImmunityBio's Shares Outstanding (Weighted Average) rose 35.71% to $945.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $945.3 million, marking a year-over-year increase of 35.71%. This contributed to the annual value of $696.8 million for FY2024, which is 4.36% up from last year.
  • Per ImmunityBio's latest filing, its Shares Outstanding (Weighted Average) stood at $945.3 million for Q3 2025, which was up 7.10% from $882.6 million recorded in Q2 2025.
  • ImmunityBio's Shares Outstanding (Weighted Average)'s 5-year high stood at $945.3 million during Q3 2025, with a 5-year trough of $109.3 million in Q1 2021.
  • For the 3-year period, ImmunityBio's Shares Outstanding (Weighted Average) averaged around $676.0 million, with its median value being $691.6 million (2024).
  • Data for ImmunityBio's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 289.72% (in 2021) over the last 5 years.
  • ImmunityBio's Shares Outstanding (Weighted Average) (Quarterly) stood at $397.6 million in 2021, then climbed by 0.68% to $400.3 million in 2022, then skyrocketed by 66.80% to $667.7 million in 2023, then increased by 4.36% to $696.8 million in 2024, then skyrocketed by 35.71% to $945.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $945.3 million in Q3 2025, compared to $882.6 million in Q2 2025 and $853.4 million in Q1 2025.